Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 3 Completed 500 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with placebo when applied topically in subjects with dry eye disease.

Timeline

Start: 2001-03
Primary completion: 2001-12
Completion: 2001-12

Publications

Results Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004 Nov;23(8):784-92. doi: 10.1097/01.ico.0000133993.14768.a9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diquafosol tetrasodium	Oligonucleotide (other)	1 %	Topical
Subject	Diquafosol tetrasodium	Oligonucleotide (other)	2 %	Topical

Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

Summary

Timeline

Publications

Drugs

Indications